Exactech Earns Breakthrough Status for JointMedica’s Polymotion Hip Resurfacing

Exactech has earned U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for JointMedica’s Polymotion hip resurfacing system. Exactech is a minority JointMedica shareholder, and is partnering with the UK-based orthopedic device maker to exclusively distribute its next-gen hip resurfacing.
 
“This designation by the FDA is a validation of our core belief at JointMedica—that our hip resurfacing device addresses an acute unmet need of relatively younger, active hip arthritis patients,” Terence Smith, managing director of JointMedica told the press.
 
According to Exactech chief strategy officer Sharat Kusuma, MD, “We are thrilled that PolyMotion and JointMedica have been recognized as one of only 71 orthopedic devices that have received breakthrough designation since the inception of this program. We aspire to accelerate Polymotion hip resurfacing development and help more patients get back to all the activities they love.”
 
The researchers designed the Polymotion system from clinically successful principles of their previous hip resurfacing devices, now with advanced polyethylene and titanium manufacturing tech. Polymotion offers hip resurfacing’s biomechanical benefits but eliminates metal-on-metal articulating surfaces.
 
“Hip Resurfacing remains an excellent choice for young, active patients, who will inevitably place a higher demand on their hip reconstruction. The introduction of metal-on-vitamin E crosslinked polyethylene hip resurfacing would be most welcomed by me as a practicing surgeon and well-received by my patient community,” added Craig J. Della Valle, MD, of Midwest Orthopaedics at Rush.